| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apogee Therapeutics, Inc. | Director | Common Stock | 34.8K | $1.3M | $37.26 | Jul 13, 2023 | Direct |
| Nuvation Bio Inc. | Chief Financial Officer | Class A Common Stock | 4.48K | $6.1K | $1.36 | Feb 28, 2023 | Direct |
| Nuvation Bio Inc. | Chief Financial Officer | Stock Option (Right to Buy) | 600K | Feb 28, 2023 | Direct | ||
| Zenas BioPharma, Inc. | Chief Business Officer and Chief Financial Officer | Stock Option (Right to Buy) | 155K | Sep 12, 2024 | Direct | ||
| Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10.4K | Jun 5, 2024 | Direct | ||
| PROKIDNEY CORP. | Director | Director stock option (right to buy) | 9.54K | Sep 3, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ZBIO | Zenas BioPharma, Inc. | Sep 12, 2024 | 1 | $0 | 4 | Sep 16, 2024 | Chief Business Officer and Chief Financial Officer |
| ZBIO | Zenas BioPharma, Inc. | Sep 12, 2024 | 0 | $0 | 3 | Sep 12, 2024 | Chief Business Officer and Chief Financial Officer. Exhibit List: Exhibit 24 - Power of Attorney |
| PROK | PROKIDNEY CORP. | Sep 3, 2024 | 1 | $0 | 4 | Sep 4, 2024 | Director |
| APGE | Apogee Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| PROK | PROKIDNEY CORP. | May 30, 2024 | 1 | $0 | 4 | Jun 3, 2024 | Director |
| APGE | Apogee Therapeutics, Inc. | Jul 13, 2023 | 0 | $0 | 3/A | Jul 17, 2023 | Director |
| PROK | PROKIDNEY CORP. | Jul 12, 2023 | 2 | $0 | 4 | Jul 13, 2023 | Director |
| NUVB | Nuvation Bio Inc. | Feb 28, 2023 | 1 | $0 | 4 | Mar 2, 2023 | Chief Financial Officer |
| PROK | PROKIDNEY CORP. | Sep 20, 2022 | 1 | $0 | 4 | Sep 22, 2022 | Director |
| NUVB | Nuvation Bio Inc. | Aug 29, 2022 | 1 | $0 | 4 | Aug 31, 2022 | Chief Financial Officer |
| PROK | PROKIDNEY CORP. | Jul 11, 2022 | 0 | $0 | 3 | Jul 13, 2022 | Director |
| NUVB | Nuvation Bio Inc. | Feb 28, 2022 | 1 | $0 | 4 | Mar 2, 2022 | Chief Financial Officer |